Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo Article

Simpkins, Fiona, Hevia-Paez, Pedro, Sun, Jun et al. (2012). Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo . CLINICAL CANCER RESEARCH, 18(21), 5911-5923. 10.1158/1078-0432.CCR-12-1257

Open Access

cited authors

  • Simpkins, Fiona; Hevia-Paez, Pedro; Sun, Jun; Ullmer, Wendy; Gilbert, Candace A; da Silva, Thiago; Pedram, Ali; Levin, Ellis R; Reis, Isildinha M; Rabinovich, Brian; Azzam, Diana; Xu, Xiang-Xi; Ince, Tan A; Yang, Ji-Yeon; Verhaak, Roel GW; Lu, Yiling; Mills, Gordon B; Slingerland, Joyce M

sustainable development goals

authors

publication date

  • November 1, 2012

webpage

published in

keywords

  • BETA
  • C-SRC
  • CARCINOMA
  • CELL-SURVIVAL
  • ESTROGEN-RECEPTOR-ALPHA
  • FAMILY KINASES
  • GROWTH
  • HUMAN-BREAST-CANCER
  • LIGANDS
  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology
  • TYROSINE KINASE

Digital Object Identifier (DOI)

publisher

  • AMER ASSOC CANCER RESEARCH

start page

  • 5911

end page

  • 5923

volume

  • 18

issue

  • 21